2025-12-17 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co. Inc. (MRK) based on the provided data.

**0) Report in English**

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **MRK Overview:** Merck & Co Inc is a global pharmaceutical company.
*   **MRK Cumulative Return:** 16.97%
*   **VOO (S&P 500) Cumulative Return:** 99.81%
*   **Divergence:** -87.1 (Relative Divergence: 13.6)

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha    | Beta   | Cap(B)  |
|------------|---------|---------|----------|--------|---------|
| 2015-2017  | 1.0%    | 68.5%   | -28.0%   | 0.0    | 134.1   |
| 2016-2018  | 36.0%   | 69.8%   | 21.0%    | -0.0   | 182.1   |
| 2017-2019  | 40.0%   | 69.8%   | 18.0%    | 0.3    | 216.8   |
| 2018-2020  | 16.0%   | 79.6%   | -8.0%    | 0.3    | 195.0   |
| 2019-2021  | 2.0%    | 79.6%   | -44.0%   | 0.7    | 191.4   |
| 2020-2022  | 15.0%   | 79.6%   | 16.0%    | 0.7    | 277.1   |
| 2021-2023  | 33.0%   | 79.6%   | 31.0%    | 0.3    | 272.3   |
| 2022-2024  | -4.0%   | 79.6%   | -25.0%   | 0.2    | 248.5   |
| 2023-2025  | -32.0%  | 71.5%   | -97.0%   | 1.8    | 245.5   |

**Analysis:**

MRK has significantly underperformed the S&P 500 (VOO) over the investment periods, with a cumulative return divergence of -87.1%.  The relative divergence of 13.6 suggests the current divergence is near the low end of its historical range.

*   **Alpha:** The Alpha values are highly variable, indicating inconsistent outperformance relative to the market.  Recent periods (2023-2025) show very negative alpha, suggesting significant underperformance.
*   **Beta:** The Beta values fluctuate between 0.0 and 1.8, indicating that MRK's price has generally moved in the same direction as the market, but to varying degrees. In the most recent period (2023-2025), a Beta of 1.8 suggests a high correlation with the market and greater volatility.
*   **CAGR:** The Compound Annual Growth Rate (CAGR) has been declining in the most recent periods, even turning negative, which confirms the stock performance is declining.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating substantial risk.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 98.27
*   **Previous Close:** 100.26
*   **Change:** -1.98
*   **5-day SMA:** 99.09
*   **20-day SMA:** 99.83
*   **60-day SMA:** 90.75

**Analysis:**

The current price is below both the 5-day and 20-day Simple Moving Averages (SMAs), suggesting a short-term downtrend.  However, the 60-day SMA is significantly lower, indicating a longer-term upward trend that may be weakening. The recent price drop is confirmed by the negative change, suggesting the downward trend in stock prices.

**3) RSI, PPO, and Divergence Analysis**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 29.25 (Oversold)
*   **PPO:** -0.76
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (10 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -5.1 (Short-term decline)
*   **Expected Return (%):** -65.3

**Analysis:**

*   The Market Risk Indicator (MRI) suggests a medium investment risk level.
*   The RSI of 29.25 indicates that the stock might be oversold and could experience a potential rebound.
*   The negative PPO value indicates a downtrend and the 20-day relative divergence change indicates a short-term decline.
*   The extremely negative Expected Return suggests that analysts forecast poor performance relative to the market over the long term.

**4) Recent News & Significant Events**

*   **Negative News:** Multiple articles highlight concerns about Merck's post-patent strategy, reassessments of Keytruda and Winrevair, and a recent stock drop. This points to potential market anxieties.
*   **Analyst Reassessments:** The news mentions analysts reassessing Keytruda, Winrevair, and Merck's post-patent strategy, indicating a period of uncertainty and potential downward revisions.
*   **Surging Stock Prior to Drop:** Some articles mention a previous surge in Merck's stock price, possibly driven by pipeline updates. This suggests recent fluctuations have been dramatic.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.97)
*   **Target Price:** 108.04 (Average)
*   **Recent Rating Changes:** Not available

**Analysis:**

Despite the recent negative news and stock price decline, the analyst consensus remains a "Buy," and the average target price is significantly above the current price. This suggests that analysts believe the stock is undervalued and has the potential for future growth. However, the lack of recent rating changes makes it difficult to determine if analysts have factored in the latest negative news.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-11-05 | 2.32 | 17.28 B$    |
| 2025-08-05 | 1.76 | 15.81 B$    |
| 2025-05-02 | 2.01 | 15.53 B$    |
| 2024-11-06 | 1.25 | 16.66 B$    |
| 2025-11-05 | 1.25 | 16.66 B$    |

**Analysis:**

Earnings Per Share (EPS) and revenue have shown fluctuations. The most recent EPS of 2.32 is the highest in the data provided, but the previous EPS had relatively flat EPS figures. The revenue shows the same fluctuation of recent growth.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.28B    | 77.69%        |
| 2025-06-30   | $15.81B    | 77.50%        |
| 2025-03-31   | $15.53B    | 77.98%        |
| 2024-12-31   | $15.62B    | 75.50%        |
| 2024-09-30   | $16.66B    | 75.51%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|--------------|------------|--------|
| 2025-09-30   | $51.85B    | 11.16% |
| 2025-06-30   | $48.99B    | 9.04%  |
| 2025-03-31   | $48.34B    | 10.51% |
| 2024-12-31   | $46.31B    | 8.08%  |
| 2024-09-30   | $44.50B    | 7.09%  |

**Analysis:**

*   **Revenue:** Revenue has shown a generally increasing trend, with the most recent quarter reporting the highest revenue.
*   **Profit Margin:** Profit margins are consistently high, indicating strong profitability.
*   **Equity:** Equity has been steadily increasing, suggesting positive capital management.
*   **ROE:** Return on Equity (ROE) has also been increasing, indicating that the company is generating more profit from shareholders' investments.

**7) Comprehensive Analysis (Summary)**

Merck (MRK) is currently facing mixed signals. While recent financial performance (revenue, profit margin, ROE) has been strong, the stock has underperformed the S&P 500 significantly. There are concerns about Merck's post-patent strategy, which are reflected in analyst reassessments and negative news sentiment. The current price is below its short-term moving averages, and the negative expected return highlights potential long-term concerns.

However, the oversold RSI and the "Buy" analyst consensus, along with a substantial target price, suggest potential for a rebound. Investors should carefully consider the risks associated with patent expirations and pipeline uncertainty, along with the potential for growth and future profitability. The recent negative headlines are also very alarming and must be addressed when considering Merck.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.